UBS Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $40

Benzinga · 2d ago
UBS analyst Ashwani Verma maintains ACADIA Pharmaceuticals (NASDAQ:ACAD) with a Buy and raises the price target from $35 to $40.